In Vitro Susceptibility Data Provided Through the University of Pittsburgh Medical Center.
In Vitro Data Should Not Be Considered Representative of Clinical Efficacy1

Established therapeutic utility in blepharitis, conjunctivitis, and other superficial ocular infections caused by Bacitracin-susceptible organisms

Excellent safety profile—low incidence of adverse events2

Ointment provides long-lasting ocular surface contact time and greater bioavailability3

Anti-infective efficacy in a lubricating base2

Flexible dosing—1 to 3 times daily2

Tier 1 pharmacy benefit status— on most insurance plans4


Bacitracin Ophthalmic Ointment is indicated for the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by Bacitracin susceptible organisms.

Important Safety Information

This product should not be used in patients with a history of hypersensitivity to Bacitracin.
Bacitracin Ophthalmic Ointment should not be used in deep-seated ocular infections or in those that are likely to become systemic.
There is a low incidence of allergenicity exhibited by Bacitracin. If such reactions do occur, therapy should be discontinued.

Click here for full prescribing information.

NDC Size Case Pack
0574-4022-35 3.5 g 144 / 12

Bioequivalency Rating: RLD

References: 1. Antibiotic susceptibility: conjunctivitis and blepharitis. University of Pittsburgh Medical Center, Charles T. Campbell Eye Microbiology Lab Web site. Accessed December 9, 2015. 2. Bacitracin Ophthalmic Ointment [package insert]. Minneapolis, MN: Perrigo Company; August 2013. 3. Hecht G. Ophthalmic preparations. In: Gennaro AR, ed. Remington: the Science and Practice of Pharmacy. 20th ed. Baltimore, MD: Lippincott Williams & Wilkins; 2000. 4. Data on file. Perrigo Company.

Quality, Affordable Self-Care Products™

Come work for a leading global self-care company.

Perrigo Careers